Explore 3 Stock Ideas & Industry Insights Download Free Report
● The key secondary measure showed a nominal p-value of 0.0077 at 60 mg.
● Acadia will remove the 30 mg arm from its Phase 3 programme.
● International medical revenue rose 17% to C$43.3 million.
● The trial enrolled 542 participants with early Alzheimer's disease.
● Management says the balance should fund operations into early 2027.
● The study compares 35 mg/kg and 50 mg/kg doses against placebo over 18 months.
● Management says the balance funds operations into the second half of 2028.
● A $100 million offering included a $40 million strategic investment by Eli Lilly.
● Second-quarter sales were $12.593 billion, up 13.0% reported and 4.8% comparable.
● Second-quarter net sales were $12,593 million, up 13.0% reported and 4.8% comparable.
Please wait processing your request...
You are not subscribed for this report, Want to See?
One of our sales representative will contact you soon!
Welcome to Kalkine!
Start Your 7-Days Free Trial Today!
Hi! How can we help you today?
Loading…